Your Best Stock
Stocks Biotechnology REGN

Regeneron Pharmaceuticals REGN

US equityMarket cap rank #199BiotechnologyInfectious Disease
$791.33
−$10.50 (-1.31%)
Market open · Sep 24, 1:10 pm ET
After hours $801.82 0.00%
Open$801.59
Prev close$801.82
Day range$789.41 – $807.21
Volume246.9K
Market cap$81.47B
P/E (TTM)19.6
Dividend yield0.46%

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$4.29B+16.7% YoY
Operating profit$1.42B+30.4% YoY
Net profit$1.30B-6.8% YoY
Diluted EPS$12.23-4.5% YoY
Free cash flow$521.80M-29.3% YoY
Operating cash flow$813.00M

Revenue, last 8 quarters

$3.7BSep '24$3.8BDec '24$3.0BMar '25$3.7BJun '25$3.8BSep '25$3.9BDec '25$3.6BMar '26$4.3BJun '26

Net profit, last 8 quarters

$1.3BSep '24$917.7MDec '24$808.7MMar '25$1.4BJun '25$1.5BSep '25$844.6MDec '25$727.2MMar '26$1.3BJun '26

Diluted EPS by quarter

11.54Sep '248.06Dec '247.27Mar '2512.81Jun '2513.62Sep '257.86Dec '256.75Mar '2612.23Jun '26

Free cash flow by quarter

$1.0BSep '24$995.8MDec '24$773.6MMar '25$737.6MJun '25$1.4BSep '25$880.0MDec '25$799.4MMar '26$521.8MJun '26

Annual revenue

$8.5BFY20$16.1BFY21$12.2BFY22$13.1BFY23$14.2BFY24$14.3BFY25

Profitability & balance sheet

Gross margin84.9%
Operating margin26.9%
Net margin27.9%
Return on equity14.0%
Return on assets10.8%
Return on invested capital11.1%
Current ratio3.34
Liabilities / assets24.0%
Cash & investments$7.99B
Total debt$1.99B
Net cash (debt)$6.01B
Free cash flow / sales23.0%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Collaboration revenue$2.46B 57.2%
  • EYLEA HD$596.30M 13.9%
  • EYLEA$412.20M 9.6%
  • Libtayo$342.60M 8.0%
  • Other revenue$193.30M 4.5%
  • Libtayo$146.80M 3.4%
  • Praluent$74.70M 1.7%
  • Evkeeza$53.30M 1.2%
  • Lynozyfic$16.50M 0.4%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $4.29B $3.61B $14.34B $3.88B $3.75B
Total Operating Revenue $4.29B $3.61B $14.34B $3.88B $3.75B
Cost of Revenue $576.50M $669.40M $2.10B $584.60M $521.60M
Gross Profit $3.71B $2.94B $12.24B $3.30B $3.23B
Operating Expense $2.29B $2.19B $8.54B $2.40B $2.12B
Selling and Admin Expenses $662.10M $647.70M $2.70B $775.00M $657.80M
Research & Development $1.63B $1.54B $5.85B $1.63B $1.48B
Operating Profit $1.42B $744.80M $3.70B $898.60M $1.11B
Net Non-Operating Interest Income (Expense) $172.30M $170.60M $673.00M $181.10M $155.80M
Non-Operating Interest Income $183.30M $183.50M $716.80M $193.30M $175.10M
Non-Operating Interest Expense $11.00M $12.90M $43.80M $12.20M $19.30M
Other Income (Expense) -$65.00M -$84.20M $855.70M -$36.00M $497.60M
Gain on Sale of Security $61.90M $25.00M $946.10M -$21.50M $577.70M
Special Income (Charges) -$127.00M -$101.90M -$124.10M -$18.70M -$83.10M
-Less:Other Special Charges $127.00M $101.90M $124.10M $18.70M $83.10M
Other Non-Operating Income (Expenses) $100,000.00 -$7.30M $33.70M $4.20M $3.00M
Pretax Profit $1.53B $831.20M $5.23B $1.04B $1.76B
Tax $230.90M $104.00M $725.80M $199.10M $303.30M
Net Profit $1.30B $727.20M $4.50B $844.60M $1.46B
Profit from Continuing Operations $1.30B $727.20M $4.50B $844.60M $1.46B
Net Income to Parent Company $1.30B $727.20M $4.50B $844.60M $1.46B
Net Income to Common Stockholders $1.30B $727.20M $4.50B $844.60M $1.46B
Basic EPS $12.62 $6.99 $43.07 $8.21 $14.09
Diluted EPS $12.23 $6.75 $41.48 $7.86 $13.62
Dividend Per Share $0.94 $0.94 $3.52 $0.88 $0.88
Other Operating Expenses -$10.00M $0.00 -$10.00M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $41.73B $40.87B $40.56B $40.56B $40.17B
Total Current Assets $18.45B $18.21B $18.02B $18.02B $17.98B
Cash and Cash Equivalents & Short-Term Investments $7.99B $8.75B $8.61B $8.61B $8.44B
-Cash and Cash Equivalents $2.46B $2.96B $3.12B $3.12B $2.51B
-Short Term Investments $5.54B $5.79B $5.49B $5.49B $5.94B
Receivables $6.57B $5.73B $5.74B $5.74B $5.69B
-Accounts Receivable $6.57B $5.73B $5.74B $5.74B $5.69B
Inventory $3.08B $3.10B $3.20B $3.20B $3.25B
Other Current Assets $801.70M $620.90M $474.80M $474.80M $595.60M
Total Non-Current Assets $23.28B $22.66B $22.54B $22.54B $22.19B
Net PPE $5.46B $5.27B $5.12B $5.12B $5.00B
Investments and Advances $9.83B $9.79B $10.26B $10.26B $10.29B
-Available for Sale Securities $9.83B $9.79B $10.26B $10.26B $10.29B
Goodwill and Other Intangible Assets $1.31B $1.29B $1.26B $1.26B $1.38B
Non-Current Deferred Assets $4.38B $4.19B $4.08B $4.08B $3.85B
Other Non-Current Assets $2.31B $2.13B $1.82B $1.82B $1.67B
Total Liabilities $10.02B $9.45B $9.30B $9.30B $9.21B
Total Current Liabilities $5.53B $5.11B $4.37B $4.37B $4.43B
Payables $1.16B $1.03B $1.29B $1.29B $903.80M
-Accounts Payable $1.16B $1.03B $939.00M $939.00M $903.80M
Current Accrued Expenses $2.97B $2.72B $2.53B $2.53B $2.98B
Short-Term Debt and Capital Lease Obligation $720.00M $720.00M
-Current Capital Lease Obligation $720.00M $720.00M
Current Deferred Liabilities $684.80M $636.20M $553.00M $553.00M $545.60M
Total Non-Current Liabilities $4.49B $4.34B $4.93B $4.93B $4.79B
Long Term Debt and Capital Lease Obligation $1.99B $1.99B $2.71B $2.71B $2.71B
-Long Term Debt $1.99B $1.99B $1.99B $1.99B $1.99B
-Long Term Capital Lease Obligation $0.00 $0.00 $720.00M $720.00M $720.00M
Non-Current Deferred Liabilities $220.40M $225.10M $208.70M $208.70M $219.20M
Other Non-Current Liabilities $2.28B $2.13B $2.02B $2.02B $1.86B
Total Equity $31.71B $31.42B $31.26B $31.26B $30.96B
Stockholders' Equity $31.71B $31.42B $31.26B $31.26B $30.96B
Capital Stock $100,000.00 $100,000.00 $100,000.00 $100,000.00 $100,000.00
-Common Stock $100,000.00 $100,000.00 $100,000.00 $100,000.00 $100,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $14.70B $14.40B $14.00B $14.00B $13.79B
Retained Earnings $37.62B $36.42B $35.80B $35.80B $35.05B
Less: Treasury Stock $20.57B $19.41B $18.61B $18.61B $17.94B
Gains/Losses Not Affecting Retained Earnings -$35.80M $11.90M $77.50M $77.50M $69.00M
-Gross PPE $7.73B $7.73B
-Accumulated Depreciation -$2.61B -$2.61B
-Other Intangible Assets $1.26B $1.26B
-Total Tax Payable $351.30M $351.30M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $813.00M $1.08B $4.98B $1.17B $1.62B
Net cash flow from continuing operations $813.00M $1.08B $4.98B $1.17B $1.62B
Net Income from Continuing Operations $1.30B $727.20M $4.50B $844.60M $1.46B
Gain/Loss from Continuing Operations -$61.90M -$25.00M -$946.10M $21.50M -$577.70M
Depreciation & Depletion & Amortization $123.70M $123.20M $543.70M $145.00M $136.70M
Deferred Tax -$194.40M -$96.00M -$785.40M -$232.50M -$278.60M
Other Non-Cash Items $54.90M $55.60M $135.50M $136.90M $16.30M
Change in Working Capital -$649.20M $36.50M $532.60M $5.90M $625.00M
-Change in Receivables -$838.50M $1.20M $498.10M -$51.20M -$80.30M
-Change in Inventory -$28.20M $26.60M -$275.30M $2.10M -$82.60M
-Change in Prepaid Assets -$319.10M -$198.60M -$375.30M $82.80M -$47.90M
-Change in Payables and Accrued Expense $492.70M $107.70M $736.80M -$24.70M $759.20M
-Change In Other Working Capital $43.90M $99.60M -$51.70M -$3.10M $76.60M
Net cash flow from investing -$92.70M -$428.90M -$629.10M $220.30M -$402.90M
Net Cash Flow from Continuing Investing Activities -$92.70M -$428.90M -$629.10M $220.30M -$402.90M
Capital Expenditure -$240.20M -$230.60M -$898.40M -$248.70M -$201.40M
Net Intangibles Purchase and Sale -$51.00M -$48.90M -$315.30M -$42.00M -$43.30M
Net Investment Purchase and Sale $198.50M -$149.40M $587.90M $511.30M -$155.20M
Financing Cash Flow -$1.22B -$802.20M -$3.72B -$780.10M -$717.90M
Net Cash Flow from Continuing Financing Activities -$1.22B -$802.20M -$3.72B -$780.10M -$717.90M
Net Common Stock Issuance -$1.13B -$704.40M -$3.33B -$687.40M -$626.70M
Cash Dividends Paid -$96.80M -$97.80M -$370.30M -$92.70M -$91.20M
Ending Cash Balance $2.47B $2.97B $3.12B $3.12B $2.51B
Net Change in Cash -$504.30M -$152.20M $634.40M $610.90M $497.90M
Beginning Cash Balance $2.97B $3.12B $2.49B $2.51B $2.02B
Effect of Exchange Rate Changes -$300,000.00 -$900,000.00 $300,000.00 -$300,000.00 -$400,000.00
Free Cash Flow $521.80M $799.40M $3.77B $880.00M $1.37B
Net PPE Purchase and Sale $0.00 $0.00 $0.00
Net Business Purchase and Sale -$3.30M -$300,000.00 -$3.00M
Net Other Financing Charges -$10.30M $0.00 $0.00
Scroll to Top